Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052)

NCT00687323 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Acute Myeloid
Myelodysplastic Syndrome

Interventions

DRUG: temozolomide

Sponsor

Merck Sharp & Dohme LLC